These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 18665181)

  • 1. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation.
    Wolter P; Stefan C; Decallonne B; Dumez H; Bex M; Carmeliet P; Schöffski P
    Br J Cancer; 2008 Aug; 99(3):448-54. PubMed ID: 18665181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
    Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
    J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
    Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
    Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
    J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
    Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.
    Desai J; Yassa L; Marqusee E; George S; Frates MC; Chen MH; Morgan JA; Dychter SS; Larsen PR; Demetri GD; Alexander EK
    Ann Intern Med; 2006 Nov; 145(9):660-4. PubMed ID: 17088579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
    Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
    Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
    Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
    Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer.
    Del Fabbro E; Dev R; Cabanillas ME; Busaidy NL; Rodriguez EC; Bruera E
    J Chemother; 2012 Aug; 24(4):221-5. PubMed ID: 23040687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
    Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
    Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
    Feldman DR; Martorella AJ; Robbins RJ; Motzer RJ
    J Natl Cancer Inst; 2007 Jun; 99(12):974-5; author reply 976-7. PubMed ID: 17565156
    [No Abstract]   [Full Text] [Related]  

  • 13. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
    Adams VR; Leggas M
    Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
    Sella A; Hercbergs AH; Hanovich E; Kovel S
    Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction?
    Rogiers A; Wolter P; Op de Beeck K; Thijs M; Decallonne B; Schöffski P
    Thyroid; 2010 Mar; 20(3):317-22. PubMed ID: 20144039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer.
    Theou-Anton N; Faivre S; Dreyer C; Raymond E
    Drug Saf; 2009; 32(9):717-34. PubMed ID: 19670913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pleural and pericardial effusions combined with ascites in a patient with severe sunitinib-induced hypothyroidism.
    Kust D; Kruljac I; Peternac AŠ; Ostojić J; Prpić M; Čaržavec D; Gaćina P
    Acta Clin Belg; 2016 Jun; 71(3):175-7. PubMed ID: 26319226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics of thyroid abnormalities induced by sunitinib treatment in Japanese patients with renal cell carcinoma.
    Sato S; Muraishi K; Tani J; Sasaki Y; Tokubuchi I; Tajiri Y; Yamada K; Suekane S; Miyajima J; Matsuoka K; Hiromatsu Y
    Endocr J; 2010; 57(10):873-80. PubMed ID: 20733268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The incidence and mechanism of sunitinib-induced thyroid atrophy in patients with metastatic renal cell carcinoma.
    Shinohara N; Takahashi M; Kamishima T; Ikushima H; Otsuka N; Ishizu A; Shimizu C; Kanayama H; Nonomura K
    Br J Cancer; 2011 Jan; 104(2):241-7. PubMed ID: 21157447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
    Pani F; Atzori F; Baghino G; Boi F; Tanca L; Ionta MT; Mariotti S
    Thyroid; 2015 Nov; 25(11):1255-61. PubMed ID: 26414109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.